Q3 2026 results · 27 October 2026

Kisqali grew 37% to $1.82bn, just $36M behind Novartis' top drug Cosentyx.

$1.82Bsales of Kisqali, up 37%

$14.5Bnet sales, up 4%

−9 ptsof growth lost to generic competition

Source

Get a note when Novartis reports next.

Whatco sends a short notification with the number that matters, and the full story of the company is a tap away.